Clinical Trial Update: An Immunogenicity and Safety Study of Sabin Inactivated Poliovirus Vaccine (Vero Cell) in 2-month-old Infants [Phase 3]

View source ↗

Summary

Phase 3 trial assessing immunogenicity and safety of Sabin Inactivated Poliovirus Vaccine (Vero Cell) in 2-month-old infants; the study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Poliomyelitis

Drugs mentioned

• Sabin Inactivated Poliovirus Vaccine (Vero Cell) (Sabin inactivated poliovirus vaccine (Vero cell))

Snippet

Sponsor: Sinovac Biotech Co., Ltd | Conditions: Poliomyelitis | Phase 3 | Status: COMPLETED